| Term 
 
        | Cholinergic-blocking agents CBA atropine (Atropair)
 |  | Definition 
 
        | inhibits the parasympathetic nervous system by competing with acetylcholine for binding muscarinic receptors. |  | 
        |  | 
        
        | Term 
 
        | Cholinergic-blocking agents CBA atropine (Atropair)
 adverse effects
 |  | Definition 
 
        | tachycardia CNS stimulation
 urinary retention in men with prostrate disorders
 dry mouth, dry eyes, decreased sweat, and photophobia
 |  | 
        |  | 
        
        | Term 
 
        | Cholinergicagents/parasympathomimetics bethanechol (Urecholine} |  | Definition 
 
        | activate the parasympathetic nervous system either directly by binding to cholinergic receptors or indirectly by inhibiting the action of AchE, which prevents the destruction of endogenous Ach so it remains on the cholinergic receptors longer and prolongs its action. |  | 
        |  | 
        
        | Term 
 
        | Cholinergic agents/parasympathomimetics bethanechol (Urecholine)
 adverse effects
 |  | Definition 
 
        | profuse salivation, increased muscle tone,
 urinary frequency, bronchoconstriction,
 bradycardia
 |  | 
        |  | 
        
        | Term 
 
        | cholinergic agents/parasympathomimetics bethanechol (Urecholine) used for treatment of:
 |  | Definition 
 
        | glaucoma, urinary retention, myasthenia gravis, and Alzheimer’s disease.  (old people stuff) |  | 
        |  | 
        
        | Term 
 
        | Cholinergic-blocking agents CBA atropine (Atropair) used for treatment of:
 |  | Definition 
 
        | Used in the treatment of : - peptic ulcers and irritable bowel syndrome
 - eye exams, to cause mydriasis or cytoplegia
 - bradycardia
 - asthma.
 |  | 
        |  | 
        
        | Term 
 
        | Adrenergic–blocking agents ABA prazosin (Minipress)
 |  | Definition 
 
        | inhibits the sympathetic nervous system and produces many of the same rest and digest symptoms of the parasympathomimetics. |  | 
        |  | 
        
        | Term 
 
        | Adrenergic-blocking agents ABA prazosin (Minipress)used for treatment of:
 |  | Definition 
 
        | hypertension, heart failure, dysrhythmias, angina, benign prostatic hypertrophy, and narrow-angle glaucoma. |  | 
        |  | 
        
        | Term 
 
        | Adrenergic-blocking agents ABA prazosin (Minipress)
 adverse effects
 |  | Definition 
 
        | dizziness, drowsiness, dry mouth,  headache, palpitations, loss of energy and strength |  | 
        |  | 
        
        | Term 
 
        | Adrenergic agents (sympathomimetics)- phenylephrine (Neo-Synephrine) |  | Definition 
 
        | stimulates the sympathetic nervous system either by: - directly, by binding to and activating adrenergic receptors, or
 - indirectly, by causing the release of norepinephrine from the presynaptic neuron or
 - by inhibiting the reuptake or destruction of norepinephrine.
 |  | 
        |  | 
        
        | Term 
 
        | Adrenergic agents Alpha 1 receptors treatment of
 |  | Definition 
 
        | treatment of nasal congestion or hypotension; causes dilation of pupils during ophthalmic examinations |  | 
        |  | 
        
        | Term 
 
        | Adrenergic agents Alpha 2 receptors treatment of
 |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Beta 1 receptors treatment of |  | Definition 
 
        | cardiac arrest, heart failure, and shock |  | 
        |  | 
        
        | Term 
 
        | Beta 2 receptors treatment of |  | Definition 
 
        | asthma and premature labor contractions |  | 
        |  | 
        
        | Term 
 
        | Adrenergic agents or sympathomimetics STIMULATE: |  | Definition 
 
        | sympathetic nervous system |  | 
        |  | 
        
        | Term 
 
        | Adrenergic antagonists or sympatholytics INHIBIT: |  | Definition 
 
        | sympathetic nervous system |  | 
        |  | 
        
        | Term 
 
        | Cholinergic or parasympathomimetics STIMULATE: |  | Definition 
 
        | parasympathetic nervous system |  | 
        |  | 
        
        | Term 
 
        | Cholingergic-blocking agents, anticholinergics, parasympatholytics, or muscarine blockers INHIBIT: |  | Definition 
 
        | parasympathetic nervous system |  | 
        |  | 
        
        | Term 
 
        | Activation of alpha 1-adrenergic receptors |  | Definition 
 
        | located in all sympathetic target organs except the heart, cause constriction of blood vessels and dilation of the pupils. |  | 
        |  | 
        
        | Term 
 
        | Activation of alpha 2-adrenergic receptors |  | Definition 
 
        | located at presynaptic adrenergic neuron terminals, inhibits the release of norepinephrine |  | 
        |  | 
        
        | Term 
 
        | Activation of beta 1-adrenergic receptors |  | Definition 
 
        | located in the heart and kidneys, increase the heart rate and the force of contraction of the heart and the release of renin from the kidneys |  | 
        |  | 
        
        | Term 
 
        | Activation of beta 2-adrenergic receptors |  | Definition 
 
        | located in all sympathetic target organs except the heart, inhibits smooth muscle |  | 
        |  | 
        
        | Term 
 
        | Activation of nicotinic receptors |  | Definition 
 
        | located in cell bodies of sympathetic and parasympathetic postganglionic neurons, stimulates smooth muscle and secretion of glands |  | 
        |  | 
        
        | Term 
 
        | Activation of muscarinic receptors |  | Definition 
 
        | located in parasympathetic target organs except the heart, stimulates smooth muscle and secretion from glands |  | 
        |  |